Literature DB >> 19000022

Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.

Matthew D Marsden1, Jie Xu, Dean Hamer, Jerome A Zack.   

Abstract

Abstract Strategies for purging persistent reservoirs in human immunodeficiency virus (HIV)-infected individuals may be enhanced by including agents that specifically kill virus-expressing cells. Anti-HIV envelope immunotoxins (ITs) represent one class of candidate molecules that could fulfill this function. We have previously utilized an anti-gp120 IT in conjunction with various stimulants to kill latently infected T cells ex vivo. Here we show that primary macrophages expressing HIV Env are relatively refractory to killing by IT when used alone. However, including stimulants such as prostratin or granulocyte-macrophage colony-stimulating factor to increase HIV gene expression in infected macrophages enhanced IT-mediated killing. Therefore, "activation-elimination" strategies similar to those proposed for purging the latent HIV reservoir may prove useful in clearing chronically infected macrophages in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000022      PMCID: PMC2928488          DOI: 10.1089/aid.2008.0082

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  53 in total

Review 1.  HIV-1 pathogenesis.

Authors:  Mario Stevenson
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

2.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  E Olsen; M Duvic; A Frankel; Y Kim; A Martin; E Vonderheid; B Jegasothy; G Wood; M Gordon; P Heald; A Oseroff; L Pinter-Brown; G Bowen; T Kuzel; D Fivenson; F Foss; M Glode; A Molina; E Knobler; S Stewart; K Cooper; S Stevens; F Craig; J Reuben; P Bacha; J Nichols
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

4.  Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

Authors:  J Kulkosky; D M Culnan; J Roman; G Dornadula; M Schnell; M R Boyd; R J Pomerantz
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

5.  Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy.

Authors:  S Sonza; H P Mutimer; R Oelrichs; D Jardine; K Harvey; A Dunne; D F Purcell; C Birch; S M Crowe
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 7.  HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication.

Authors:  S M Crowe; S Sonza
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

8.  In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.

Authors:  Seth H Pincus; Hua Fang; Royce A Wilkinson; Tamera K Marcotte; James E Robinson; William C Olson
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

9.  Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.

Authors:  Christian T Ruff; Stuart C Ray; Patricia Kwon; Rebekah Zinn; Amanda Pendleton; Nancy Hutton; Roxann Ashworth; Stephen Gange; Thomas C Quinn; Robert F Siliciano; Deborah Persaud
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.

Authors:  Louise McHugh; Stella Hu; B K Lee; Kenneth Santora; Paul E Kennedy; Edward A Berger; Ira Pastan; Dean H Hamer
Journal:  J Biol Chem       Date:  2002-07-15       Impact factor: 5.486

View more
  8 in total

1.  Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.

Authors:  Elizabeth J Beans; Dennis Fournogerakis; Carolyn Gauntlett; Lars V Heumann; Rainer Kramer; Matthew D Marsden; Danielle Murray; Tae-Wook Chun; Jerome A Zack; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-28       Impact factor: 11.205

2.  Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.

Authors:  Jie Lan; Kai Yang; Daniel Byrd; Ningjie Hu; Tohti Amet; Nicole Shepherd; Mona Desai; Jimin Gao; Samir Gupta; Yongtao Sun; Qigui Yu
Journal:  J Immunol       Date:  2014-08-22       Impact factor: 5.422

3.  Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Anderson Frank; David Worthylake; Hye-Kyung Chung; Patricia Polacino; Dean H Hamer; Cody P Coyne; Michael G Rosenblum; John W Marks; Gang Chen; Deborah Weiss; Victor Ghetie; Ellen S Vitetta; James E Robinson; Shiu-Lok Hu
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

4.  Establishment and maintenance of HIV latency: model systems and opportunities for intervention.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Future Virol       Date:  2010-01-01       Impact factor: 1.831

Review 5.  Eradication of HIV: current challenges and new directions.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  J Antimicrob Chemother       Date:  2008-11-04       Impact factor: 5.790

6.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

7.  Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Authors:  Ryan B Craig; Christopher M Summa; Miriam Corti; Seth H Pincus
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

8.  HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.

Authors:  Nitin K Saksena; Bin Wang; Li Zhou; Maly Soedjono; Yung Shwen Ho; Viviane Conceicao
Journal:  HIV AIDS (Auckl)       Date:  2010-06-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.